Oncolines is expanding its lab capacity with a new screening lab including cell culture facilities. All activities in this lab will focus on the profiling of compounds in the Oncolines 102 cancer cell line panel to identify drug response biomarkers, new disease indications, and synergistic drug combinations. In addition, Oncolines offers in-depth bioinformatics analysis presented in interactive reports for a faster and easier interpretation of the results.

About Oncolines
Oncolines B.V. is a precision medicine services company in oncology and cancer immunotherapy. We help to bring improved and novel therapies to the right patient population faster. We offer a set of complimentary services to enable our clients to characterize their compounds, and to determine activities, selectivities and mechanism of action. We present results in a unique and interactive reporting format that facilitates easier and faster interpretation of results.